Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,244.00+0.48%ETH$2,243.45+1.84%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
EV

NASDAQ · EVO

Evotec SE

Healthcare · Drug Manufacturers - Specialty & Generic

$1.58

Down-$0.05 (-3.16%)

Updated Oct 30, 2026, 11:40 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.08B
P/E ratio
-6.02
Dividend yield
0.00%
52-week range
$1.33 – $3.41
Volume
64.14K
Avg. volume
69.26K

Price performance · EVO

EVO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

EVO closed at $1.58 after 21 trading sessions, down 3.95% for the selected period.

Last close
$1.58
Period change
-3.95%
Period low
$1.35
Period high
$1.66
Daily close
View OHLC price history
EVO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$1.59$1.59$1.55$1.5864.14K
Oct 28, 2026$1.57$1.61$1.57$1.605145.67K
Oct 27, 2026$1.52$1.57$1.52$1.5742.42K
Oct 26, 2026$1.51$1.54$1.51$1.52121.49K
Oct 23, 2026$1.50$1.53$1.50$1.5020.61K
Oct 22, 2026$1.56$1.56$1.53$1.5451.81K
Oct 21, 2026$1.50$1.56$1.50$1.5653.02K
Oct 20, 2026$1.43$1.49$1.43$1.4885.71K
Oct 19, 2026$1.41$1.44$1.41$1.4277.57K
Oct 16, 2026$1.43$1.43$1.38$1.3882.4K
Oct 15, 2026$1.44$1.44$1.39$1.42123.98K
Oct 14, 2026$1.48$1.48$1.41$1.425158.37K
Oct 13, 2026$1.345$1.35$1.33$1.345113.96K
Oct 12, 2026$1.44$1.44$1.36$1.37182.62K
Oct 9, 2026$1.56$1.57$1.53$1.5340.01K
Oct 8, 2026$1.59$1.595$1.5304$1.5794.42K
Oct 7, 2026$1.60$1.63$1.58$1.6193.14K
Oct 6, 2026$1.73$1.73$1.605$1.63195.01K
Oct 5, 2026$1.61$1.73$1.61$1.66341.98K
Oct 2, 2026$1.63$1.63$1.5907$1.6052.03K
Oct 1, 2026$1.69$1.70$1.645$1.645119.05K

Latest EVO news

The latest Smart Investors Daily articles mentioning EVO.

Stock researchCompany · Overview

EVO research

Overview

Company profile and research snapshot.

Company profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
EVO recent ratings
DateFirmRatingTarget
Sep 21, 2026BERENBERGHold—
Aug 13, 2026TD COWENHold—
Jul 16, 2026EQUI.TSNeutral—
Jun 30, 2026TD COWENBuy—
Jun 29, 2026TD COWENBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 25, 2026

Did Evotec’s 60% Drop Catch You Out? What Investors Missed

Evotec’s latest announcement landed hard. Management cut its 2026 revenue and EBITDA guidance after partnership milestones slipped, then reported weaker Q2 2026 figures with a deeper net loss. For Evotec shareholders, the loss over the past year was 59.7%, including dividends. If you had put money into the stock in October 2025, how should this outcome influence your view of whether delays in partnerships or the broader business model deserve closer scrutiny next? The move put Evotec in the...

Yahoo · Oct 15, 2026

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Her experience spans multi-modal 'omics, data science, novel therapeutic

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By